Latest progress

Recently, Salubris announced that Enarodustat tablet was approved by NMPA to carry out clinical trial for new indication (treatment of anemia caused by chemotherapy in patients with non-myeloid malignant tumors, hereinafter referred to as "CIA").

Enarodustat（恩那罗^®）, is a new generation of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), currently marketed for the treatment of anemia in non-dialysis adult patients with chronic kidney disease (CKD).

If successfully developed and approved for marketing, this new indication will provide new options for CIA patients and better address unmet clinical needs in this area.

| About Enarodustat（恩那罗^®）

As a new generation of HIF-PHI, the action of Enarodustat on HIF-PH is more reasonable, which improves erythropoiesis steadily through increasing endogenous production of erythropoietin levels within or near normal physiologic range. (Source: Phase 3 clinical trial results and label)